A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)

替扎尼定 医学 不良事件报告系统 不利影响 药理学 麻醉 内科学 痉挛
作者
Lorenzo Villa‐Zapata,Ainhoa Gómez-Lumbreras,John R. Horn,Malinda S. Tan,Richard D. Boyce,Daniel C. Malone
出处
期刊:Drug Safety [Springer Nature]
卷期号:45 (8): 863-871 被引量:7
标识
DOI:10.1007/s40264-022-01200-4
摘要

Tizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events.Our aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2.A disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture.A total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest. More than half of the reports identified tizanidine as having a suspect or interacting role (n = 59, 66.3%), and the reports more frequently involved women (n = 58, 65.1%). The median age was 56.1 years (standard deviation 17.1). Some of the important safety signals included interactions between tizanidine in a suspect or interacting role and ciprofloxacin (ROR for hypotension 28.1, 95% confidence interval [CI] 19.2-41.2) or fluvoxamine (ROR for hypotension 36.9, 95% CI 13.1-103.4), and also when reported in "any role" with ciprofloxacin (ROR for hypotension 6.3, 95% CI 4.7-8.5), fluvoxamine (ROR for hypotension 11.4, 95% CI 4.5-28.8), and zafirlukast (ROR for falls 16.0, 95% CI 6.1-42.1).Reports involving tizanidine and a CYP1A2 inhibitor have higher odds of reporting hypotension. This study suggests that concurrent use of tizanidine with CYP1A2 inhibitors may lead to serious health consequences associated with low blood pressure such as falls and fractures.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小白一号完成签到 ,获得积分10
刚刚
Cynthia完成签到 ,获得积分10
刚刚
李惊鸿完成签到,获得积分10
刚刚
刚刚
刚刚
愤怒的子骞完成签到,获得积分10
1秒前
Emilia完成签到,获得积分10
2秒前
3秒前
烩面大师发布了新的文献求助10
3秒前
鲍binyu完成签到,获得积分10
4秒前
Hello应助猪猪hero采纳,获得10
4秒前
今后应助xiuxiu_27采纳,获得10
5秒前
5秒前
jjy发布了新的文献求助10
5秒前
5秒前
在人类完成签到,获得积分10
5秒前
哈雷彗星完成签到,获得积分10
5秒前
系统提示发布了新的文献求助10
5秒前
luca驳回了Orange应助
6秒前
孙二二完成签到,获得积分10
6秒前
迷人圣诞树很闲完成签到,获得积分10
6秒前
优秀的修洁完成签到 ,获得积分10
6秒前
7秒前
7秒前
7秒前
顺心的惜蕊完成签到,获得积分10
7秒前
7秒前
Lucas应助等待的乐儿采纳,获得10
8秒前
嘉梦完成签到,获得积分10
8秒前
激动的从霜完成签到,获得积分10
8秒前
大门神发布了新的文献求助10
8秒前
思源应助xiaokezhang采纳,获得10
9秒前
10秒前
swsx1317完成签到,获得积分10
10秒前
从容飞凤发布了新的文献求助10
10秒前
皮卡皮卡完成签到 ,获得积分10
11秒前
无花果应助qq小兵采纳,获得10
11秒前
11秒前
1111发布了新的文献求助10
12秒前
小马甲应助bwbw采纳,获得10
13秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527699
求助须知:如何正确求助?哪些是违规求助? 3107752
关于积分的说明 9286499
捐赠科研通 2805513
什么是DOI,文献DOI怎么找? 1539954
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709759